Modus Therapeutics to Present LPS Study Data at Pharmacology 2024
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, December 10, 2024 – Modus Therapeutics announces that data from its Phase 1b LPS study will be presented as a poster at the British Pharmacological Society Annual Meeting (Pharmacology 2024) in Harrogate, UK, on December 10–12. The study data that was disclosed in reporting during 2023, explores the effects of sevuparin, on local and systemic inflammation induced by the bacterial toxin lipopolysaccharide (LPS) in healthy volunteers.
The poster, titled "Sevuparin effects on local and systemic LPS-induced inflammation in healthy volunteers," summarizes results from the randomized, double-blind, placebo-controlled Phase 1b study in 71 healthy participants and will be presented by Dr de Bruin from our collaborators at the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands.
Key findings as previously reported from the study include:
- Sevuparin was well tolerated across all dose groups, with no clinically relevant adverse effects.
- In the systemic LPS challenge, sevuparin significantly increased circulating levels of basophils, neutrophils, and lymphocytes at the highest dose level.
- A near significant effect of sevuparin was observed on respiratory rate.
- No significant differences compared to placebo were observed for other systemic or local measures.
“This poster presentation underlines the maintained interest in the effects observed in this study, and together with the favorable safety profile of sevuparin, it underlines our unchanged confidence in its potential as a treatment for acute inflammatory conditions such as sepsis and endotoxemia,” said John Öhd, CEO of Modus Therapeutics.
The poster will be presented on December 10 from 13:45 to 15:15 CET.
Modus Therapeutics continues to evaluate sevuparin’s role in addressing significant medical needs and looks forward to sharing further updates on its clinical development.